NZ630831A - Compositions and methods for administration of vaccines against dengue virus - Google Patents

Compositions and methods for administration of vaccines against dengue virus

Info

Publication number
NZ630831A
NZ630831A NZ630831A NZ63083113A NZ630831A NZ 630831 A NZ630831 A NZ 630831A NZ 630831 A NZ630831 A NZ 630831A NZ 63083113 A NZ63083113 A NZ 63083113A NZ 630831 A NZ630831 A NZ 630831A
Authority
NZ
New Zealand
Prior art keywords
dengue virus
administration
compositions
methods
vaccines against
Prior art date
Application number
NZ630831A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jorge E Osorio
Charalambos D Partidos
Joseph N Brewoo
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of NZ630831A publication Critical patent/NZ630831A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ630831A 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus NZ630831A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus
PCT/US2013/045041 WO2013188315A1 (en) 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus

Publications (1)

Publication Number Publication Date
NZ630831A true NZ630831A (en) 2019-02-22

Family

ID=48652375

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630831A NZ630831A (en) 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus

Country Status (6)

Country Link
EP (1) EP2858668A1 (OSRAM)
JP (2) JP2015520196A (OSRAM)
CA (1) CA2915027A1 (OSRAM)
NZ (1) NZ630831A (OSRAM)
TW (1) TW201402143A (OSRAM)
WO (1) WO2013188315A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
ES2933970T3 (es) 2013-03-15 2023-02-15 Takeda Vaccines Inc Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas
JP2018522880A (ja) 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルス及び樹状細胞による併用療法のための組成物及び方法
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
CA3020484A1 (en) * 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
CN110139671A (zh) 2016-11-16 2019-08-16 普莱瓦克斯免疫肿瘤学公司 用于治疗癌症的组合免疫疗法
WO2018129202A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
NZ618158A (en) * 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Also Published As

Publication number Publication date
JP2015520196A (ja) 2015-07-16
CA2915027A1 (en) 2013-12-19
TW201402143A (zh) 2014-01-16
EP2858668A1 (en) 2015-04-15
JP2018090618A (ja) 2018-06-14
WO2013188315A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
EP4218807A3 (en) Zika virus vaccine
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
MX384875B (es) Método para obtener una vacuna de mycoplasma.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
MA39743A (fr) Fumarate de diméthyle et régimes de vaccination
MX2016007224A (es) Vacuna contra el circovirus porcino tipo 2.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
GB2515222A (en) Use of flagellin as a vaccine
WO2013173256A3 (en) New and improved influenza vaccines
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
IN2013DE02372A (OSRAM)
UA69683U (ru) Способ лечения больных стеатогепатитом

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed